Literature DB >> 7635609

Model-based estimates of the risk of human immunodeficiency virus and hepatitis B virus transmission through unsafe injections.

B Aylward1, M Kane, R McNair-Scott, D J Hu, D H Hu.   

Abstract

BACKGROUND: Patient-to-patient transmission through contaminated medical equipment may be the principal route of nosocomial blood-borne infections globally. Quantifying cross infection risks could facilitate efforts to ensure safe injections in developing countries.
METHOD: A mathematical model was developed to evaluate the risk of cross infection due to unsafe injections. The model was applied to immunization programmes with a fixed number of injections and in which unsterile needle and syringe reuse rates were specified. Risk estimates were generated using a range of human immunodeficiency virus (HIV) and hepatitis B (HBV) prevalences.
RESULTS: The risk of cross infection is zero when properly sterilized equipment is used. With unsafe injections, the risk of cross infection with HBV is consistently higher than HIV for comparable levels of endemicity. A single reuse of each needle and syringe in areas with an HBeAg prevalence of 4% results in 980 cases of HBV/100,000 infants; reuse four times results in 3740 cases. When the HIV prevalence is 1% and the reuse rate is 4, 14 to 35 cases of HIV/100,000 women could occur. Contamination of multidose vaccine vials could considerably increase these estimates.
CONCLUSIONS: Neither HIV nor HBV transmission has been reported with injections administered through the Expanded Programme on Immunization. However, ample evidence exists that reuse of unsterile needles and syringes is common in developing countries. Ongoing efforts to ensure safe practices and improve injection technologies are required to protect these populations from both medical and traditional skin-piercing procedures.

Entities:  

Mesh:

Year:  1995        PMID: 7635609     DOI: 10.1093/ije/24.2.446

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  7 in total

Review 1.  Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates.

Authors:  Yvan J F Hutin; Anja M Hauri; Gregory L Armstrong
Journal:  BMJ       Date:  2003-11-08

2.  Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.

Authors:  Milton Maciel; David Bauer; Robin L Baudier; Jacob Bitoun; John D Clements; Steven T Poole; Mark A Smith; Robert W Kaminski; Stephen J Savarino; Elizabeth B Norton
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

3.  Reducing the risk of unsafe injections in immunization programmes: financial and operational implications of various injection technologies.

Authors:  B Aylward; J Lloyd; M Zaffran; R McNair-Scott; P Evans
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

4.  Risk of infection from needle reuse at a phlebotomy center.

Authors:  T C Porco; T J Aragón; S E Fernyak; S H Cody; D J Vugia; M H Katz; D R Bangsberg
Journal:  Am J Public Health       Date:  2001-04       Impact factor: 9.308

5.  Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey.

Authors:  Josephine Bwogi; Fiona Braka; Issa Makumbi; Vinod Mishra; Barnabas Bakamutumaho; Miriam Nanyunja; Alex Opio; Robert Downing; Benon Biryahwaho; Rosamund F Lewis
Journal:  Afr Health Sci       Date:  2009-06       Impact factor: 0.927

Review 6.  Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.

Authors:  Birgitte Giersing; Natasha Shah; Debra Kristensen; Jean-Pierre Amorij; Anna-Lea Kahn; Kristoffer Gandrup-Marino; Courtney Jarrahian; Darin Zehrung; Marion Menozzi-Arnaud
Journal:  Vaccine       Date:  2021-10-07       Impact factor: 3.641

Review 7.  The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.

Authors:  John D Clements; Elizabeth B Norton
Journal:  mSphere       Date:  2018-07-25       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.